Pharmacogenomics study for prediction of treatment effects and side effects in pancreatic cancer

2016 Fiscal Year Final Research Report

• Project/Area Number: 26870099
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Gastroenterology; Medical genome science
• Research Institution: Chiba University
• Principal Investigator: SATO YASUNORI 千葉大学, 大学院医学研究院, 准教授 (90536723)
• Research Collaborator: YOSHIDA TERUHIKO ; OKUSAKA TAKUSHI ; UENO HIDEKI ; Laird Nan
• Project Period (FY): 2014-04-01 – 2017-03-31
• Keywords: 膵癌 / ゲノム網羅的解析 / ファーマコゲノミクス / バイオマーカー / 薬剤反応性遺伝子 / 生物統計手法

Outline of Final Research Achievements

We employed genome-wide pharmacogenomics studies to identify candidate polymorphisms that could influence overall survival (OS) or adverse effects (AEs) in advanced pancreatic cancer (PC) patients. As a result, advanced PC patients with the rs4149086 AG or GG genotype may obtain good clinical results when treated with S-1 containing regimens. Additionally, we detected the candidate SNPs which could influence OS or AEs in genome-wide association study (GWAS). And also, we developed a new statistical method for detecting candidate SNPs in a GWAS.

Free Research Field

生物統計